上海医药(02607.HK)斥约9.95亿人币购上海和黄药业10%股权

阿斯达克财经01-02

上海医药(02607.HK) 公布，去年12月31日与和黄投资订立股份转让协议。据悉，上海医药同意向和黄投资收购“上海和黄药业”10%股权，代价约9.95亿元人民币。
同日，上海医药独立第三方金浦健服与和黄投资订立股份转让协议。据悉，金浦健服或其指定主体将向和黄投资收购“上海和黄药业”35%股权。截至昨日(1日)，上海和黄药业由和黄投资及上海医药全资附属公司上药药材分别持有50%股权。

于收购事项完成后，“上海和黄药业”将由上海医药直接及间接持有60%股权，并将成为该公司的非全资附属公司，且其财务业绩将综合计入集团综合财务报表内。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2500968294?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","is_english":false,"pubTime":"2025-01-02 08:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500968294","market":"fut","top_or_hot":-1,"title":"上海医药(02607.HK)斥约9.95亿人币购上海和黄药业10%股权","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/601607\">上海医药</a>(02607.HK)<span> </span>公布，去年12月31日与和黄投资订立股份转让协议。据悉，<a href=\"https://laohu8.com/S/02607\">上海医药</a>同意向和黄投资收购“上海和黄药业”10%股权，代价约9.95亿元人民币。<br/>同日，上海医药独立第三方金浦健服与和黄投资订立股份转让协议。据悉，金浦健服或其指定主体将向和黄投资收购“上海和黄药业”35%股权。截至昨日(1日)，上海和黄药业由和黄投资及上海医药全资附属公司上药药材分别持有50%股权。<br/><span></span><br/>于收购事项完成后，“上海和黄药业”将由上海医药直接及间接持有60%股权，并将成为该公司的非全资附属公司，且其财务业绩将综合计入集团综合财务报表内。(js/w)<br/>(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上海医药(02607.HK)斥约9.95亿人币购上海和黄药业10%股权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上海医药(02607.HK)斥约9.95亿人币购上海和黄药业10%股权\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2025-01-02 08:27</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/601607\">上海医药</a>(02607.HK)<span> </span>公布，去年12月31日与和黄投资订立股份转让协议。据悉，<a href=\"https://laohu8.com/S/02607\">上海医药</a>同意向和黄投资收购“上海和黄药业”10%股权，代价约9.95亿元人民币。<br/>同日，上海医药独立第三方金浦健服与和黄投资订立股份转让协议。据悉，金浦健服或其指定主体将向和黄投资收购“上海和黄药业”35%股权。截至昨日(1日)，上海和黄药业由和黄投资及上海医药全资附属公司上药药材分别持有50%股权。<br/><span></span><br/>于收购事项完成后，“上海和黄药业”将由上海医药直接及间接持有60%股权，并将成为该公司的非全资附属公司，且其财务业绩将综合计入集团综合财务报表内。(js/w)<br/>(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1407255/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海国资改革","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1407255/latest-news/AAFN","article_id":"2500968294","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500968294","pubTimestamp":1735777620,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"上海医药公布，去年12月31日与和黄投资订立股份转让协议。据悉，上海医药同意向和黄投资收购“上海和黄药业”10%股权，代价约9.95亿元人民币。截至昨日，上海和黄药业由和黄投资及上海医药全资附属公司上药药材分别持有50%股权。于收购事项完成后，“上海和黄药业”将由上海医药直接及间接持有60%股权，并将成为该公司的非全资附属公司，且其财务业绩将综合计入集团综合财务报表内。(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601607":"上海医药","BK0184":"上海国资改革","BK0188":"融资融券","BK0028":"国家队","BK1197":"保健护理产品经销商","BK0209":"零售","BK0187":"一线龙头","BK0183":"MSCI概念","BK0012":"证金概念","BK0196":"行业龙头","02607":"上海医药","BK0175":"白马股","BK0097":"医药电商","BK0020":"浦东新区","BK0099":"上海本地重组"},"translate_title":"Shanghai Pharmaceuticals (02607. HK) spent approximately RMB 995 million to purchase 10% equity of Shanghai Hutchison Pharmaceuticals","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"上海医药(02607.HK) 公布，去年12月31日与和黄投资订立股份转让协议。据悉，上海医药同意向和黄投资收购“上海和黄药业”10%股权，代价约9.95亿元人民币。同日，上海医药独立第三方金浦健服与和黄投资订立股份转让协议。据悉，金浦健服或其指定主体将向和黄投资收购“上海和黄药业”35%股权。截至昨日(1日)，上海和黄药业由和黄投资及上海医药全资附属公司上药药材分别持有50%股权。于收购事项完成后，“上海和黄药业”将由上海医药直接及间接持有60%股权，并将成为该公司的非全资附属公司，且其财务业绩将综合计入集团综合财务报表内。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500968294"}